|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of the Registrant
|
On November 27, 2020, Clovis Oncology, Inc. (the “Company”) completed the sale of $7,500,000 aggregate principal amount of its 4.50% Convertible Senior Notes due 2024 (the “Additional Notes”) at a purchase price of $1,000 per $1,000 principal amount of Additional Notes. The Additional Notes were sold pursuant to the terms of that certain Exchange and Purchase Agreement, dated as of November 4, 2020, by and between the Company and the holder named therein (the “Holder”) pursuant to the Holder’s exercise of its option to purchase such notes, granted in connection with the previously disclosed private offering of $50 million aggregate principal amount of the Company’s 4.50% Convertible Senior Notes due 2024 to the Holder (the “Initial Notes” and, together with the Additional Notes, the “Notes”), which initial offering closed on November 17, 2020. The Additional Notes have the same terms, and were issued under the same Indenture, dated as of November 17, 2020, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Indenture”), as the Initial Notes, as described in the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020 and November 17, 2020 (the “Form 8-Ks”). The information set forth in the Form 8-Ks are incorporated herein by reference.
The Additional Notes were offered and sold pursuant to the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended, (the “Securities Act”). The offer and sale of the Additional Notes and the shares of common stock issuable upon conversion of the Additional Notes have not been registered under the Securities Act or any state securities laws, and, unless so registered, the Additional Notes and such shares may not be offered or sold in the United States except pursuant to an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.
The Company intends to use the net proceeds from the sale of the Additional Notes for general corporate purposes, including repayment, repurchase or refinance of its debt obligations, sales and marketing expenses associated with Rubraca® (rucaparib), funding of its development programs, payment of milestones pursuant to its license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.
These descriptions of the Indenture and the Additional Notes are qualified in their entirety by reference to the Indenture and Form of Global Note, which are filed as Exhibit 4.1 and 4.2, respectively, to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 17, 2020 and incorporated herein by reference.
This current report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy the Additional Notes.